Although the majority of cutaneous melanoma patients are non-Hispanic white (NHW), minorities consistently suffer worse melanoma specific survival (MSS). Much of the literature comes from analyses of registries from the 1990s and 2000s.
Archive | Health Professionals
The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (SEER) database (1975-2016)
Posted in Melanoma News, Health Professionals, Of Interest
Scientists identify key driver in BRAF inhibitor resistant melanoma
Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
Posted in Melanoma News, Health Professionals, Of Interest
Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma
TAMPA, Fla. — Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
Posted in Melanoma News, Health Professionals, Of Interest
Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma
Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the OpACIN and OPACIN-neo trials examining ipilimumab (Yervoy) plus nivolumab (Opdivo) in stage III macroscopic melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
